Multimedia

Multimedia

Podcasts and video interviews with researchers, commentators, and experts in the field

video

PERSIST-1: Pacritinib Shakes Up the Current Myelofibrosis Treatment Landscape

Ruben A. Mesa, MD, discusses the JAK2 inhibitor pacritinib, which led to better symptom control and improved cytopenias in patients with myelofibrosis. Read more...
video

David Sargent, PhD: Complete Response at 30 Months: A Surrogate for PFS in First-Line...

With median progression-free survival reaching seven years in first-line follicular lymphoma patients, evaluating new treatments is difficult. Daniel Sargent, PhD, describes an easier-to-assess, accurate...
video

SIRIUS: Promising Results for Daratumumab in Hard-to-Treat Myeloma Patients

Saad Zafar Usmani, MD, shares the “unprecedented” results from the phase II trial of the anti-CD38 monoclonal antibody daratumumab in patients with double refractory...

Investigational Drug BLU-285 Shows Tolerable Safety, Early Clinical Activity in Patients With Advanced Systemic...

Data from an ongoing phase I trial of BLU-285, an oral inhibitor of KIT D816V, in patients with advanced systemic mastocytosis (SM) suggest that...

Age, Comorbidity, Time on Chemotherapy Predict Increases in Hospitalizations, ER Visits Among CLL Patients

Researchers identified several risk factors leading to greater health-care resource use, including age, comorbidity burden, presence of adverse events, and duration of therapy, in...
Advertisement

Current Issue

February 2019, Volume 5, Issue 3

This issue features a look at the unique challenges of developing treatments for orphan diseases, more coverage of the 2018 ASH annual meeting, and more.